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Abstract
Prostate cancer (PCa) is the most commonly diagnosed
cancer in American men with a subset inevitably
presenting with metastatic disease to the bone. A well-
recognized limitation in evaluating new treatments for
metastatic PCa is the inability to use imaging to ob-
jectively assess response therapy. In this study, we
evaluated the feasibility of clinically translating the
functional diffusion map (fDM) imaging biomarker for
quantifying the spatiotemporal effects of bone tumor
response in a patient treated for metastatic PCa with
bone metastases. A patient beginning therapy was
scanned using MRI before treatment and again at 2 and
8weeks post–treatment initiation to quantify changes in
tumor diffusion values. Three metastatic lesions were
identified for fDM analysis, all of which all demonstrated
an early increase in diffusion values at 2 weeks, which
increased further at 8 weeks post–treatment initiation.
This finding correlated with a decrease in the patient’s
prostate-specific antigen (PSA) levels suggestive of
patient response. CT, bone scans, and anatomic MRI
images obtained posttreatment were found to be unin-
formative for the assessment of treatment effectiveness.
This study presents the feasibility of fDMmeasurements
in osseous lesions over time and shows that changes in
fDM values were consistent with therapeutic response.
Thus, the fDM imaging biomarker may provide a quan-
tifiable therapeutic endpoint to assess response in pa-
tients with metastatic bone cancer.
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Introduction
In 2007, approximately 218,890 men would have been di-
agnosed with prostate cancer (PCa) and 27,050 men in the
United States are expected to die of PCa [1]. The mortality is
directly related to the development of metastatic disease,
which is incurable, thus requiring the development of improved
therapies [2]. One of the main limitations in evaluating new
treatments for metastatic PCa is the inability to use available
clinical imaging modalities to assess treatment response in
bone, which is the predominant and often the only site of
metastasis in 85% to 90% of patients [3,4].
Currently, assessments of tumor response in bone using cri-
teria defined by the International Union Against Cancer [5,6],
the World Health Organization [7], and the Response Evalua-
tion Criteria in Solid Tumors (RECIST) [8] group do not meet
the needs of oncologists in clinical practice [9]. In fact, the
RECISTsystem considers bone disease to be unmeasureable.
Traditional clinical assessment of bony metastases is achieved
through radionuclide bone scintigraphy. Although considered to
be the standard screening technique for assessing the entire
skeleton for metastases, it is well recognized that this imaging
technique lacks the specificity needed to accurately distinguish
metastatic lesions from areas of abnormal radionuclide uptake
due to inflammation, degeneration, or trauma, as well as to
measure early therapeutic response. Although the use of bone
scintigraphy, computed tomography (CT), and magnetic reso-
nance imaging (MRI) plays a distinct role in identifying and
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characterizing the extent of disease, the use of these tech-
niques for the assessment of treatment response is limited.
To overcome these limitations, prostate-specific antigen
(PSA) alterations have been explored as a screening tool
for antitumor effect. A decline in PSA of at least 50% is a
widely accepted measure for antitumor effect; however, the
use of PSA endpoints have not been prospectively validated
as fulfilling surrogacy requirements for clinical benefit in any
setting [10]. Therefore, development and validation of an
imaging technology which would be capable of reliably and
accurately measuring antitumor effect in metastatic bone
disease would provide a significant advance and aide in
the timely investigation of new therapeutic agents not only
for PCa but also for other malignancies common to the bone
(i.e., metastatic breast cancer and primary bone cancers).
The use of diffusion MRI for assessing response to anti-
cancer therapy is based on its ability to quantify the random
or Brownian motion of water. Diffusion of water within a tumor
is reduced in the presence of cellular membranes that act to
impede the random motion of water molecules. During the
course of successful treatment, loss of tumor cells and/or
tumor cell membrane integrity occurs, which will then result
in a reduction in the barriers that impede mobility of water
molecules. Diffusion MRI can be used to assess the treat-
ment effect through quantification of the amount of increased
apparent diffusion coefficient (ADC) values in tumor regions
experiencing a loss of cellular density. Thus, water mobility
within a tumor will increase over time following effective
treatment, as represented by an increase in MRI-quantified
ADC values, with the magnitude of the change related to the
effectiveness of the therapy. This principle was first initially
demonstrated using a 1,3-bis(2-chloroethyl)-1-nitrosourea–
treated 9L glioma model [11] and was successfully extended
in a variety of preclinical studies assessing the response to
anticancer agents including: cytotoxic and cytostatic thera-
pies, radiation therapy, and gene therapy [12–34]. Moreover,
the treatment-induced changes in tumor diffusion values
were shown to be an early event as they preceded changes
in tumor growth kinetics and regression providing the ratio-
nale for using this imaging biomarker as an early predictive
marker of treatment response [13]. However, the response
of ADC to therapy in the clinical setting was found to be
more complex to quantify due to inherent pretreatment and
posttreatment heterogeneity observed within human tu-
mors requiring the development of an alternative postpro-
cessing approach known as the functional diffusion map
(fDM) [35,36]. Thus, the fDM approach was developed to
standardize the processing of clinical diffusion MRI data to
provide for a sensitive and quantifiable means for early
assessment of cancer treatment outcome.
The fDM approach of monitoring anticancer therapy al-
lows spatial, voxel by voxel tracking of changes in tumor
water diffusion values over time. Changes in diffusion values
are depicted in fDM images by color encoding of tumor
diffusion voxels that were altered due to therapy (either
increased or decreased ADC value), thereby allowing for a
spatially resolved analysis of ADC within an individual le-
sion. The initial demonstration of this novel technique was
achieved in a study involving patients with primary malignant
brain tumors where the amount of fDM-detected change in
diffusion values was found to correlate with overall clinical
response [35]. In a more recent study, we analyzed patients
with grade III/IV gliomas using fDM, which demonstrated that
this technique was able to stratify patients as responsive or
nonresponsive to therapy as early as 3 weeks into a 6- to
7-week fractionated therapy schedule, which was later con-
firmed using traditional outcome measures including radio-
logic response, time to progression, and overall survival [37].
In this study, patients identified by fDM as nonresponsive had
significantly shorter survival and time to progression com-
pared to patients identified as responsive. Moreover, further
investigation of the fDM approach in preclinical dose esca-
lation studies revealed that this approach was indeed pre-
dictive of therapeutic efficacy and, more importantly, highly
correlative with traditional outcome measures (cell kill and
overall survival) [36]. As such, the fDM technique has shown
significant promise as an early imaging-based biomarker for
treatment response.
We have recently extended and evaluated the fDM ap-
proach outside of CNS tumors for providing an early indication
of treatment response in a preclinical model of metastatic PCa
to the bone. Using PC3 PCa xenografts with confirmed bone
metastases, a correlation between changes in fDM and tumor
response to docetaxel treatment was found as early as 7 days
post–treatment initiation [16]. This preclinical finding provided
the rationale for a pilot clinical trial to assess the feasibility and
the ability of the fDM biomarker in predicting response to
systemic therapy in patients with metastatic hormone sensi-
tive and hormone refractory PCa. Our hypothesis is that the
fDM biomarker can be successfully translated into the clinical
setting for early assessment of bone tumor response arising
from metastatic PCa. In this report, we summarize data from
the first registered patient, which indicate that this approach is
clinically feasible. Briefly, our findings demonstrate a correla-
tion between diffusion changes, as determined by fDM anal-
ysis, and a decrease in PSA levels consistent with a positive
treatment response. Moreover, traditional analysis of diffusion
MRI data by mean ADC changes failed to provide a clear
indication of diffusion changes attributable to positive treat-
ment response, whereas the fDM biomarker provided a
sensitive and quantitative readout of diffusion changes within
the lesions over time. This study demonstrates for the first
time the feasibility and potential use of a standardized,
quantifiable imaging biomarker for assessing early treatment
response of skeletal tumors.
Materials and Methods
Patient Information
The clinical trial was approved by the University of
Michigan Institutional Review Board. A hormone-naı¨ve
68-year-old male with newly diagnosed metastatic PCa was
consented and was enrolled into the study. He was initiated on
combined androgen blockade with bicalutamide and goserelin
acetate. Magnetic resonance imaging scans were acquired at
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baseline, 2 and 8 weeks post–treatment initiation. Due to pain
and pathologic fracture, the patient was also treated with
palliative radiation therapy encompassing the sacrum and
ilium at 2 weeks post initiation of androgen deprivation therapy.
Clinical Correlates
Serum samples were obtained at weeks 0 (baseline), 2,
and 8 following treatment initiation. Prostate-specific antigen
levels were quantified and expressed in grams per milliliter
(g/ml) of plasma.
Bone Scintigraphy
A whole-body bone scan (BS) was performed by admin-
istering 25.8 mCi of Tc-99m methylene diphosphonate
(MDP) and gamma camera images of the entire skeleton
obtained 4 hours later (Siemens Medical Solutions, Malvern,
PA). Nuclear imaging was performed 2 weeks before and
2 months after initiation of androgen deprivation therapy.
Computed Tomography
Computed tomography (CT) of the pelvis was performed
without IV contrast on a 16-slice helical scanner (General Electric
Medical Systems, Milwaukee, WI). Two hundred two axial
sections of 2.5 mm thickness were acquired using 140 kVp,
590 mA, 0.8 sec/revolution, and a 512 matrix over a 36-cm field
of view.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) examinations including
diffusion-weighted and standard anatomic sequences were
performed before and 2 weeks after initiation of therapy. MR
imaging was performed on a 3-T scanner (Achieva model;
Philips Medical Systems, Bothell, WA) using a quadrature
body coil for transmission and a six-channel cardiac coil for
reception. Standard sequences for depiction of anatomy and
tumor extent included axial proton density (repetition time
[TR]/echo time [TE] = 2700/30 msec, two averages) turbo
spin-echo and axial T2-weighted turbo spin-echo (TR/TE =
7800/60 msec, two averages) with fat suppression through a
short inversion time (TI = 200 msec). Geometry for these
sequences was as follows: field of view, 281 mm right/left by
200 mm anterior/posterior; thirty-eight 4-mm sections with a
1-mm gap; 256  232 acquisition matrix for proton density;
and 248  165 for T2-weighted scans. Diffusion-weighted
scans were acquired using fat-suppressed, single-shot, spin-
echo, echo-planar imaging to reduce motion artifact and
parallel imaging (SENSE factor = 2) to reduce spatial distor-
tion. Geometry of the diffusion-weighted scans was as
follows: 350 mm right/left by 302 mm anterior/posterior; thirty
5-mm sections with a 1-mm gap; 200  172 acquisition
matrix; TR/TE = 2000/58 msec; and 8 averages for low (b =
0 sec/mm2) and 16 averages for high (b = 800 sec/mm2)
diffusion-sensitivity scans. Apparent diffusion coefficient
(ADC) maps were calculated in the routine manner given
by the logarithm of the ratio of low-b and high-b images, then
scaled by the inverse of b-value difference.
Diffusion Analysis
Lesions in MR images acquired at weeks 2 and 8 were
coregistered to their corresponding pretreatment MR images
using an automatic algorithm based on maximizing mutual
information. Registration was accomplished for each indi-
vidual tumor located in the sacrum, ilium, and femoral head
regions after the images were cropped to localize the regis-
tration to a limited region-of-interest (ROI) containing a single
lesion. Lesions were manually contoured by a radiologist
who defined the ROI by inspection of all available image
data. Diffusion-average data were generated for weeks 0, 2
and 8 using the ROI contours of each of the three lesions and
the mean change in diffusion values were calculated. Com-
putation of fDMs for each lesion at weeks 2 and 8 was
accomplished by comparison of voxels within the tumor at
weeks 2 and 8 with the pretreatment values (week 0) as
previously described [35,37] using MIAMI Fuse (University of
Michigan, Ann Arbor, MI) [38]. The tumor was segmented
into three different categories wherein the red voxels repre-
sent regions within the tumor where ADC values increased
(>26  105 mm2/sec), the blue voxels represent a de-
creased ADC (<26  105 mm2/sec), and the green regions
represent tumor diffusion values that were within these
thresholds (e.g., unchanged). These thresholds were deter-
mined to be the 95% confidence intervals that were calcu-
lated using the variation in the adjacent muscle tissue as a
test region, which should have unaltered diffusion values
following registration at weeks 2 and 8 posttreatment. The
percentage of tumor within each of the three categories was
then calculated as VI (% red voxels), V0 (% green voxels),
and VD (% blue voxels). In this feasibility study, all fDM
values reported represent the values computed using VI.
Statistical Analysis
Statistical analysis was accomplished using Microsoft
Excel using Student’s t test to compare changes in diffusion
at different time points and between fDM and average ADC
measurements. As this is a feasibility study wherein we are
reporting the data analysis of three lesions from a single
patient, the significance of the fDM changes in terms of
correlation with clinical outcome measures will require addi-
tional patients.
Results
Identification of Metastatic Disease and Characterization of
Osseous Lesions
At the time of initial diagnosis, the patient underwent
Tc-99m MDP BS to ascertain the extent of skeletal involve-
ment. As shown in Figure 1A, posterior BS revealed two
large areas of increased uptake in the sacrum (red arrow)
and left femoral head (yellow arrow), with two additional
smaller foci of uptake in each ilium (green arrow denotes
lesion analyzed by fDM). Nine weeks after initiation of
androgen deprivation therapy, a follow-up BS was obtained
(Figure 1B) revealing the continuing presence of previous
identified lesions; however, the uptake in these regions
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appeared more intense with greater uptake of the radionu-
clide. Visualization by CT revealed mixed lucency and scle-
rosis within the left femoral head lesion (Figure 2A, yellow
arrow). After receiving androgen deprivation therapy for
7 weeks, increased sclerosis was observed by CT (Figure 2B,
yellow arrow). Computed tomographic images of the sacral
lesion before treatment (Figure 2C, red arrow) revealed a
predominantly lytic morphology within the sacrum; however,
interval-increased sclerosis was observed after therapy
(Figure 2D, red arrow). Computed tomographic images of
the right ilium lesion (Figure 2C, green arrow) before treat-
ment revealed similar morphology to the lesion in the sa-
crum with increased sclerosis observed following treatment
(Figure 2D, green arrow). Further characterization of the
lesions was achieved by MRI. Proton density–weighted
images of the femoral head lesion revealed the presence
of heterogeneous marrow replacement (Figure 3A, yellow
arrow), with an apparent increase of low signal after 7 weeks
of treatment (Figure 3B, yellow arrow). Similarly, the sacral
and ilium lesions from proton density–weighted MR images
exhibited heterogeneous marrow replacement (Figure 3C,
red and green arrows, respectively), with increased low
signal after treatment (Figure 3D).
Tumor volumes were quantified using ROI analysis of
each of the three tumors evaluated using T2-weighted MR
images at weeks 0, 2, and 8 post–treatment initiation. As
shown in Table 1, tumor volumes were similar at the pre-
treatment time point (week 0) and at weeks 2 and 8 post-
treatment. Overall, tumor volume measurements were
unable to detect significant perturbations in tumor size in
the 8-week timeframe following treatment initiation.
fDM Analysis of Osseous Lesions Reveal Changes in
Tumor Diffusion Subsequent to Therapy
Using the fDM approach, diffusion MRI data from the
femoral head, sacral, and ilium lesions were analyzed to
detect spatial changes in tumor diffusion. As shown in Fig-
ure 4A, fDM analysis of tumor diffusion after 2 weeks of
therapy revealed regions within the femoral head lesion
(yellow arrow) that had significant increases in diffusion
(depicted as red voxels). Analysis revealed that 21.1% of
the total analyzed volume had significant increase in ADC at
week 2 posttreatment. A small region of tumor was not
analyzed in this lesion due to overlap with abdominal fat
signal due to inadequate fat suppression that occurred on
that time interval. The sacral and ilium lesions also exhibited
distinct areas of increased ADC (red voxels) (Figure 4, C
and E, respectively), which were found to be 26.4% and
24.5% of the tumor volume at 2 weeks posttreatment. After
8 weeks of therapy, fDM analysis of the femoral head, sacral,
and ilium lesions again identified regions of increased diffu-
sion values (encoded as red voxels on fDM), signifying areas
of increased diffusion within these three lesions (Figure 4, B,
D, and F, respectively). Quantification of fDM scatter plots
revealed regions of increased ADC to be 36.4% (femoral
head lesion), 29.0% (sacral lesion), and 47.1% (ilium lesion)
of the tumor volume at 8 weeks posttreatment.
Analysis of Tumor-Average Diffusion MRI Data
Lesion-mean ADC values were generated by the average
of ADC values within a volume of interest defined on each
lesion. Lesion volumes of interest were defined for the fem-
oral head, sacral, and ilium lesions. Before treatment initia-
tion, baseline mean ADC values of the femoral head, sacral,
and ilium lesions were determined to be 74.5 106, 110.8
106, and 78.0  106 mm2/sec, respectively. As the patient
underwent treatment, the femoral head lesion exhibited little
change in tumor mean diffusion where mean ADC values
were determined to be 77.8  106 mm2/sec at 2 weeks
and 76.8  106 mm2/sec at 8 weeks posttreatment. The
sacral lesion revealed an approximate 10% decrease in
mean ADC values to 99.8  106 mm2/sec at 2 weeks
post–treatment initiation, which later increased by nearly
5% above baseline at 8 weeks (116.2  106 mm2/sec). The
ilium lesion revealed very little change in mean ADC at
week 2 (80.7 106 mm2/sec) and a 16.7% increase in mean
ADC to 91.1  106 mm2/sec at 8 weeks post–treatment
initiation. Comparison of the fDM and mean ADC analysis
approaches was accomplished and the results are displayed
in Figure 5. For each tumor, the percentage change of mean
Figure 1. Bone scintigraphy. Posterior bone scintigraphic image of the pelvis shows increased uptake of the sacrum and left femoral head lesions, with two
additional foci of uptake in each ilium. Follow-up bone scintigraphy 9 weeks after therapy shows increased intensity of the uptake.
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ADC values from baseline was calculated at 2 and 8 weeks
post–treatment initiation. The average fDM percent increase
in diffusion fDM values, which represents the percent of
tumor volume with increased diffusion values, was 24 ±
1.6% and 38 ± 5.2% at weeks 2 and 8, respectively. How-
ever, the mean percentage change from baseline for the
three lesions obtained from the mean ADC analysis was
0.7 ± 4.7% and 8.3 ± 4.3% at 2 and 8 weeks, respectively.
Figure 2. Computed tomography. Axial CT images (A) before and (B) 7 weeks after treatment show a mixed lucent and sclerotic metastasis (yellow arrow) of the
left femoral head. Axial CT images reveal the sacral lesion (red arrow) and ilium lesion (green arrow) (C) before and (D) 7 weeks after treatment.
Figure 3. T1-weighted MRI. Axial T1-weighted MR images of the femoral head (A) before and (B) 7 weeks after treatment show heterogeneous marrow
replacement (yellow arrow). Axial T1-weighted MR images of the sacrum (red arrow) and ilium (green arrow) (C) before and (D) 7 weeks after treatment.
Functional Diffusion Map and Prostate Cancer Lee et al. 1007
Neoplasia . Vol. 9, No. 12, 2007
Clinical Response Assessment
PSA levels were monitored over the course of treatment.
At week 0, PSA levels were 10.7 ng/ml and were significantly
reduced at weeks 2 and 8 posttreatment to 1.3 ng/ml
and 0.3 ng/ml, respectively. The PSA levels indicated that
the patient was responding to androgen deprivation, which
is also reflected in the fDM but not in the mean-derived
ADC values.
Discussion
Bony metastases are the leading cause of morbidity and
mortality from PCa. A continuing challenge for the clinical
management of this disease is the lack of imaging tools that
can assess response in bone accurately [39]. This has
negatively impacted drug development in this disease [40].
Although imaging modalities such as BS, CT, and MRI play
important diagnostic and staging roles, the complex nature of
osseous lesions limit the utility of these imaging technologies
for accurately measuring response [41]. Part of the difficulty
in using conventional anatomic imaging (CT and MRI) for
assessing tumor volumetric changes as is typically accom-
plished in nonskeletal tumor sites for treatment response
assessment is the fact that the bone undergoes constant
remodeling with a strict coordination in the dynamic interac-
tion between osteoclasts and osteoblasts to maintain proper
Figure 4. Functional diffusion maps. Regional changes of ADC are plotted on the image to provide a visual representation of areas with increased ADC (red
voxels), decreased ADC (blue voxels), and areas where ADC did not change significantly (green voxels). fDM analysis of the femoral head lesion (yellow arrows) at
(A) 2 and (B) 8 weeks after treatment initiation revealed distinct regions of red voxels signifying areas with significant increases in ADC (>26  106 mm2/s). fDM
analysis of the sacral lesion (red arrows) at (C) 2 and (D) 8 weeks after treatment revealed significant regions of increased ADC as depicted by the red voxels. fDM
analysis of the ilium lesion (green arrows) at (E) 2 and (F) 8 weeks after treatment show large regions of increased ADC values (red voxels).
Table 1. Tumor Volume Measurements over Time.
Tumor Site Pretreatment (cm3) Week 2 (cm3) Week 3 (cm3)
Femoral Head 52.97 51.52 51.35
Sacrum 68.29 69.46 72.21
Ilium 2.34 2.76 2.56
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homeostasis. Lesions residing in the bone deregulate this
dynamic process and thus can present as osteolytic lesions,
osteoblastic lesions, or mixed lesions when visualized by
imaging, complicating interpretation and potentially con-
founding assessment of treatment-specific effects. Thus,
current recommendations on the use of these imaging tech-
niques for monitoring treatment response widely differ de-
pending on recommendations established from various
studies, hence no consensus has been established for the
validity of using BS, CT, or MRI for assessing treatment
response in bone cancer patients.
Although the data presented here are limited to one patient
with multifocal disease, the results presented clearly estab-
lish the feasibility of acquiring and processing fDM data for
metastatic bone lesions. The results confirm previous find-
ings, which have reported that bone scintigraphy following
treatment can yield false-positive images termed the flare
phenomenon where an apparent increase in radiotracer
uptake after treatment occurs [42,43]. The increased uptake
can occur with increased sclerosis of the abnormality; how-
ever, whether the increased sclerosis is due to bone healing
of a lytic tumor or a potentially blastic component of a tumor
cannot be differentiated, thus making its use in early treat-
ment response assessment problematic. In fact, data pre-
sented in Figure 1 show that at 8 weeks following treatment,
an increased uptake of the radiotracer probe (Tc-99m MDP)
was observed. Similar lack of treatment response information
was also encountered in the anatomic CT (Figure 2) and MR
(Figure 3) scans, where increased density from CT and
increased low signal on MRI could represent a positive
response to therapy from necrosis and healing. However, a
blastic component of a negative response could not be clearly
ruled out, thereby resulting in false-positive assessments.
Furthermore, radiologic response of tumors outside of the
skeletal system is currently quantified in terms of the magni-
tude of reduction in tumor volume after a specific time interval
following conclusion of treatment. As shown in Table 1, tumor
volumes for each of the lesions evaluated in this patient were
not significantly reduced at 2 or 8 weeks post–treatment
initiation revealing the lack of prognostic information obtained
from this imaging metric. In most solid tumors, volume is
proportional to the radiographic observed lesion size. How-
ever, this fact is not necessarily the case for bone metastasis
following cytotoxic treatment as most radiologists rely on the
extent of bone destruction, which is at best an indirect
assessment of tumor extent [9]. The killing of tumor cells
located in bony tumors may not result in a detectable loss of
tumor size as the lesion volume can be contained within a
bone structural deficit and, because bone regrowth does not
take place, a decrease in the size of the radiographic lesion
does not occur. In fact, this is consistent with the findings in
the patient’s images shown in Figures 2 and 3, which do not
reveal a reduction in tumor volume over time.
Quantification of the Brownian motion of water molecules
within the tumor tissue can be accomplished using MRI by
using an image acquisition sequence which makes the MR
signal intensity dependent on water mobility [44]. Clinical
translation of diffusion MRI for cancer treatment assessment
was initially accomplished in brain tumor patients [13] with
other tumor sites reported in subsequent additional studies
[45,46]. However, the analysis of diffusion data in clinical
cancer trials has been hampered by the tremendous hetero-
geneity of pretreatment diffusion values and therapeutic-
induced changes over time. Whereas analysis of mean ADC
has proved useful for syngeneic and human xenograft tumor
models, the sensitivity of this approach for the detection of
treatment-induced changes in tumor diffusion values has
been more limited in human trials due to the underlying his-
tologic heterogeneity commonly exhibited in human cancers.
To better illustrate this point in this study, we also compared
the mean ADC approach to evaluate the sensitivity of this
method for the detection of treatment response in osseous
lesions from serial diffusion ADC maps. The fDM approach
has been proposed as a means to standardize the analysis
of clinical diffusion data that relies on a voxel by voxel
comparison of diffusion changes over time. This is accom-
plished by acquiring a pretreatment ADC map of the tumor
and digitally registering the same tumor acquired at an addi-
tional time point post–treatment initiation. The fDM analysis
provides an opportunity to quantify spatiotemporal altera-
tions in tumor diffusion values in an individual tumor in terms
of total change in diffusion values as a function of percent of
total tumor volume [16,35–37].
The feasibility of applying the fDM imaging biomarker to
assess treatment response in multifocal metastatic PCa to the
bone in the clinical setting was evaluated in this study. MRI
data from three lesions arising from the femoral head, sacral,
and ilium were analyzed at 2 and 8 weeks post–treatment
initiation to evaluate for changes in tumor fDM values. fDM
analysis of each of the three lesions revealed that as early as
2 weeks, significant increases in diffusion values were found
for each tumor site. The fDM analysis revealed a very in-
teresting finding that an average 24.0% (range 21.1% to
26.4%) of the total analyzed tumor volume had a significant
increase in ADC at as early as the 2-week measurement
Figure 5. Comparison of mean ADC versus fDM with respect to pre-therapy
baseline. At 2 weeks post-therapy, a decrease of 0.7 ± 4.8% was observed by
comparing mean ADC whereas fDM demonstrated a 24 ± 1.6% increase in
ADC. At 8 weeks, mean ADC increased by 8.3 ± 4.3% whereas fDM
demonstrated a 38 ± 5.2% increase in ADC.
Functional Diffusion Map and Prostate Cancer Lee et al. 1009
Neoplasia . Vol. 9, No. 12, 2007
(Figure 5). At 8 weeks following treatment initiation, fDM
analysis of the femoral head, sacral, and ilium lesions
revealed an average of 37.5% (range 29% to 47.1%) of the
total tumor volume was found to exhibit increased diffusion
values over pretreatment baseline measurements. Although
PSA levels are not definitive measures of patient outcome,
PSA measurements from this patient revealed a decline of
88% and 97% at weeks 2 and 8, respectively. This is a
consistent but not definitive proof of an overall positive re-
sponse [10]. Although the data presented herein are from only
a single patient, the results obtained raise very interesting
opportunities for future studies. For example, it is interesting to
note that in a patient with multifocal metastatic disease, each
of the tumors evaluated was significantly impacted by the
treatment as detected by the fDM biomarker readout. This is
consistent with current clinical data, which have shown that
hormone naive patients have a high (85%) response rate [47].
The preliminary data presented in Figure 5 also reveal that
the fDM analysis of bone tumors was significantly different
from mean ADC analysis (P = .004 and P = .006 at 2 and
8weeks, respectively) and provided for amuchmore sensitive
and robust detection of treatment-induced diffusion changes
versus the conventional mean ADC approach. In fact, the lack
of significant change in tumor diffusion based on mean ADC
values obtained from data at 2 and 8 weeks (P = .116) would
suggest that androgen deprivation therapy had little effect on
the femoral head, sacral, and ilium lesions potentially leading
to the conclusion that the treatment was ineffective. In stark
contrast, the fDM analysis of the same lesions revealed that
large changes in tumor diffusion values had in fact occurred
and significantly increased over time (P = .034). Although
further clinical data need to be acquired to verify this fact, it
appears that fDM measurements from this patient with PCa
and with evidence of bone metastases are consistently more
sensitive to treatment response than the traditional meanADC
values, as has been reported in themouse PCa study [16] and
clinical brain tumor studies [35,37]. Overall, these data show
the feasibility of pursuing the use and validation of fDM for
assessment of metastatic PCa treatment monitoring as it
provides a potential, standardized approach for the analysis
of diffusion clinical tumor response data.
Optimally, routine implementation of an imaging bio-
marker for treatment assessment should not be overly time
consuming, cost-prohibitive, or difficult to access or implement
in the myriad of clinical settings worldwide. In these regards,
acquisition of diffusion MRI data in the clinical setting re-
quires only a few additional minutes of scan time which can
be accomplished without the need for contrast. Calculation of
diffusion ADC maps is available on commercial scanners
and fDM analysis will soon be accomplished using commer-
cially available software (I-Response, Cedara Software,
Mississauga, ON, Canada). Moreover, as diffusion MRI
measurements are a biophysical measurement of water
mobility, diffusion values are considered to be independent
of magnet field strength and scanner type. Therefore, imple-
mentation of this technology within a multicenter trial would
be relatively straightforward, allowing for validation of this
approach in a large-scale clinical trial. Finally, the ability to
conduct whole-body diffusion MRI interrogation of dissemi-
nated skeletal disease will offer a unique opportunity to
assess overall tumor response [48–50]. As shown in this
present study, three lesions were followed using fDM over
time, thus revealing the overall feasibility of using this
imaging biomarker for whole-body response assessment.
Validation of fDM in further studies as a quantitative and
early imaging biomarker for assessment of treatment re-
sponse in patients with metastatic PCa would be a major
leap forward for designing clinical trials and for overall patient
management. Ultimately, acceptance of the fDM biomarker
would require multicenter trials and a consensus to revise the
International Union Against Cancer, World Health Organiza-
tion, and RECIST response criteria to incorporate this imag-
ing biomarker. The successful validation and inclusion of fDM
into clinical response criteria could provide for an integrated
consensus regarding how to evaluate most accurately the
treatment response of osseous lesions.
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